Bio Saga Blog - A Chronicle of Life Sciences & Informatics

Science jobs from Polyclone Bioservices Pvt. Ltd. Location:Bangalore(India) Designation: Scientist (Bioinformatics) Qualifications: M.Sc/ PhD Experience: 0 – 1 yrs Requirements: • Candidates will have strong knowledge using–and coding functionality that interacts with–public nucleotide and protein sequence databases, sequence alignment software, and related computational genomic resources. • Strong background in sequence analysis, genome annotation, analysis of gene or protein expression, protein structure or docking prediction, comparative genomics is a must. A broad knowledge of statistics and statistical methods used in analyzing genomics data is preferred. Desirable: • C# under the .Net Framework as well as Perl. • Knowledge of the R\Bioconductor programming language • Strong background in multi-univariate and Bayesian statistics, and some experience in machine-learning techniques (SVM, NN). • We welcome expertise in Python, Bioperl, Ruby, Java, C++/C, and Matlab • Understanding o...

Roche Diagnostics said today that it has struck a deal with Salt Lake City-based BioMicro Systems to buy all of the products associated with the Roche NimbleGen microarray workflow. These assets include instruments that are key to the Roche NimbleGen microarray workflow, such as the 4-and-12-bay NimbleGen Hybridization Systems. Roche said that it will transfer the manufacturing capabilities associated with these products to its own in-house facility. "Acquiring these assets will allow Roche complete control over the production, support, and service of these products to ensure continued timely distribution, full support, and the high level of service our customers have grown to expect from Roche," Roche NimbleGen VP of Marketing Andreas Görtz said in a statement. NimbleGen originally partnered with BioMicro for custom hybridization for its chips in 2007, before it was acquired by Roche later that year. Financial terms of the agreement were not released.

Merck KGaA has entered into a definitive agreement to acquire Millipore for $7.2 million in a cash deal that would create a life science research products giant with around $2.9 billion in annual revenues. The firms announced the deal yesterday — several days after reports that Thermo Fisher Scientific had made a $6 billion bid for Millipore. Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion. "By combining Millipore's bioscience and bioprocess knowledge with our own expertise in serving pharma customers, we will be able to unlock value in our chemicals business and transform it into a strong growth driver for Merck," Karl-Ludwig Kley, chairman of the executive board of Merck KGaA. "Through this acquisition, we will expand the overall product offering of the Merck Group, using the...